Beta Bionics, Abbott Integrate iLet with Dual Glucose-Ketone Sensor

Beta Bionics and Abbott have agreed to integrate Beta Bionics' iLet automated insulin delivery system with Abbott's upcoming dual glucose-ketone sensor, enhancing real-time diabetes management by allowing continuous monitoring of glucose and ketone levels. This marks the third partnership for Abbott's dual sensor, which aims to help detect early rises in ketone levels to prevent diabetic ketoacidosis. Abbott is also collaborating with Tandem Diabetes Care on a similar integration, aiming to combine advanced insulin delivery with dual sensing technology for improved patient outcomes. Meanwhile, the future of glucose monitoring may become less invasive with the development of a breathalyzer device inspired by a dog's nose, currently undergoing preclinical testing and aiming for FDA approval. Despite these technological advances, experts remain skeptical about the benefits of continuous glucose monitors (CGMs) for non-diabetics, noting a lack of proven health benefits outside diabetic management. Additionally, a recall affecting over 2 million Dexcom glucose monitors highlights ongoing safety concerns in diabetes monitoring devices.